Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Goodwill (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Goodwill for 7 consecutive years, with $8.4 million as the latest value for Q2 2025.

  • On a quarterly basis, Goodwill rose 201.79% to $8.4 million in Q2 2025 year-over-year; TTM through Jun 2025 was $8.4 million, a 201.79% increase, with the full-year FY2024 number at $2.8 million, down 1.51% from a year prior.
  • Goodwill was $8.4 million for Q2 2025 at Vivos Therapeutics, up from $2.8 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $8.4 million in Q2 2025 to a low of $2.7 million in Q1 2021.
  • A 5-year average of $3.1 million and a median of $2.8 million in 2022 define the central range for Goodwill.
  • Peak YoY movement for Goodwill: decreased 1.51% in 2023, then soared 201.79% in 2025.
  • Vivos Therapeutics' Goodwill stood at $2.8 million in 2021, then grew by 1.54% to $2.8 million in 2022, then changed by 0.0% to $2.8 million in 2023, then decreased by 1.51% to $2.8 million in 2024, then skyrocketed by 201.79% to $8.4 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Goodwill are $8.4 million (Q2 2025), $2.8 million (Q1 2025), and $2.8 million (Q4 2024).